Robert Paul Hasserjian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 73 | 2024 | 1393 | 11.750 |
Why?
|
| Leukemia, Myeloid, Acute | 67 | 2024 | 3609 | 7.820 |
Why?
|
| Myeloproliferative Disorders | 41 | 2024 | 609 | 7.550 |
Why?
|
| Bone Marrow | 62 | 2024 | 2911 | 5.970 |
Why?
|
| Leukemia, Erythroblastic, Acute | 10 | 2018 | 176 | 2.480 |
Why?
|
| Chromosome Aberrations | 24 | 2023 | 1767 | 2.280 |
Why?
|
| World Health Organization | 17 | 2024 | 1321 | 1.970 |
Why?
|
| Hodgkin Disease | 12 | 2022 | 1378 | 1.800 |
Why?
|
| Mutation | 70 | 2024 | 30006 | 1.760 |
Why?
|
| Leukemia, Myeloid | 7 | 2019 | 693 | 1.760 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 5 | 2022 | 15 | 1.460 |
Why?
|
| Hematologic Neoplasms | 16 | 2023 | 1895 | 1.440 |
Why?
|
| Lymphoma, Follicular | 11 | 2024 | 457 | 1.340 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 2 | 2019 | 13 | 1.240 |
Why?
|
| Janus Kinase 2 | 14 | 2024 | 559 | 1.210 |
Why?
|
| Leukocytosis | 4 | 2016 | 251 | 1.200 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1051 | 1.160 |
Why?
|
| Reticulin | 4 | 2014 | 19 | 1.110 |
Why?
|
| Hypereosinophilic Syndrome | 5 | 2023 | 97 | 1.090 |
Why?
|
| Immunophenotyping | 25 | 2022 | 1867 | 1.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2020 | 686 | 1.080 |
Why?
|
| Primary Myelofibrosis | 7 | 2023 | 208 | 1.080 |
Why?
|
| Chromosome Deletion | 4 | 2017 | 1386 | 0.980 |
Why?
|
| Diagnosis, Differential | 48 | 2022 | 12975 | 0.970 |
Why?
|
| Prognosis | 51 | 2024 | 29672 | 0.960 |
Why?
|
| Calreticulin | 4 | 2020 | 113 | 0.900 |
Why?
|
| Leukemia | 11 | 2023 | 1518 | 0.900 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 10 | 2022 | 495 | 0.900 |
Why?
|
| Lymph Nodes | 13 | 2021 | 3461 | 0.890 |
Why?
|
| Hematologic Diseases | 4 | 2023 | 496 | 0.880 |
Why?
|
| Bone Marrow Examination | 10 | 2017 | 155 | 0.860 |
Why?
|
| Bone Marrow Cells | 10 | 2021 | 2410 | 0.850 |
Why?
|
| Tandem Repeat Sequences | 2 | 2022 | 180 | 0.850 |
Why?
|
| Humans | 277 | 2024 | 761098 | 0.830 |
Why?
|
| Karyotyping | 9 | 2017 | 1171 | 0.810 |
Why?
|
| Thrombocythemia, Essential | 3 | 2018 | 113 | 0.800 |
Why?
|
| Leukemia, Eosinophilic, Acute | 1 | 2021 | 5 | 0.790 |
Why?
|
| Nuclear Proteins | 19 | 2023 | 5781 | 0.780 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2020 | 92 | 0.750 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 58946 | 0.740 |
Why?
|
| Biopsy | 29 | 2023 | 6781 | 0.730 |
Why?
|
| Oral Ulcer | 1 | 2021 | 96 | 0.730 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2022 | 2914 | 0.720 |
Why?
|
| Core Binding Factors | 1 | 2020 | 29 | 0.700 |
Why?
|
| Flow Cytometry | 15 | 2022 | 5870 | 0.700 |
Why?
|
| Lymphoma, B-Cell | 7 | 2015 | 938 | 0.700 |
Why?
|
| Neoplasm Proteins | 6 | 2022 | 3594 | 0.680 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2011 | 127 | 0.680 |
Why?
|
| Aged | 106 | 2024 | 169266 | 0.660 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2011 | 101 | 0.650 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2024 | 430 | 0.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2024 | 1405 | 0.650 |
Why?
|
| Herpesvirus 4, Human | 9 | 2022 | 1076 | 0.650 |
Why?
|
| Thymus Neoplasms | 4 | 2015 | 274 | 0.640 |
Why?
|
| Pancytopenia | 4 | 2016 | 102 | 0.630 |
Why?
|
| Gene Rearrangement | 9 | 2022 | 1125 | 0.620 |
Why?
|
| Pathology, Clinical | 2 | 2019 | 376 | 0.610 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.600 |
Why?
|
| Male | 148 | 2024 | 360675 | 0.590 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2019 | 179 | 0.590 |
Why?
|
| Adult | 114 | 2024 | 221083 | 0.590 |
Why?
|
| Ring Chromosomes | 1 | 2017 | 26 | 0.590 |
Why?
|
| Polycythemia Vera | 3 | 2017 | 161 | 0.580 |
Why?
|
| Eosinophilia | 5 | 2024 | 557 | 0.570 |
Why?
|
| Abdomen | 1 | 2023 | 1128 | 0.570 |
Why?
|
| Middle Aged | 118 | 2024 | 220835 | 0.570 |
Why?
|
| Phosphoproteins | 4 | 2020 | 2443 | 0.570 |
Why?
|
| Chromosome Inversion | 2 | 2017 | 119 | 0.570 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 50 | 0.560 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2021 | 125 | 0.550 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 3 | 2022 | 30 | 0.550 |
Why?
|
| Burkitt Lymphoma | 3 | 2010 | 335 | 0.540 |
Why?
|
| Biological Products | 2 | 2023 | 913 | 0.540 |
Why?
|
| Hematology | 2 | 2023 | 243 | 0.540 |
Why?
|
| Megakaryocytes | 4 | 2018 | 566 | 0.530 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2194 | 0.530 |
Why?
|
| Mastocytosis, Systemic | 2 | 2023 | 102 | 0.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2015 | 1372 | 0.520 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2022 | 614 | 0.520 |
Why?
|
| Female | 134 | 2024 | 392458 | 0.510 |
Why?
|
| Fatal Outcome | 12 | 2012 | 1837 | 0.510 |
Why?
|
| DNA Copy Number Variations | 4 | 2024 | 2024 | 0.510 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1549 | 0.510 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2015 | 48 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2017 | 343 | 0.500 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 442 | 0.500 |
Why?
|
| Anemia, Macrocytic | 1 | 2015 | 53 | 0.500 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 1008 | 0.490 |
Why?
|
| Genetic Testing | 3 | 2019 | 3536 | 0.490 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.480 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 355 | 0.480 |
Why?
|
| Lymphoma | 8 | 2024 | 1898 | 0.480 |
Why?
|
| Myeloid Cells | 3 | 2018 | 821 | 0.480 |
Why?
|
| Immunohistochemistry | 27 | 2022 | 11066 | 0.470 |
Why?
|
| Thymoma | 2 | 2007 | 188 | 0.470 |
Why?
|
| Mediastinal Neoplasms | 3 | 2016 | 401 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2019 | 11732 | 0.470 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2021 | 5667 | 0.460 |
Why?
|
| DNA Mutational Analysis | 11 | 2022 | 4109 | 0.460 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2019 | 6482 | 0.450 |
Why?
|
| Neoplasms | 15 | 2023 | 22125 | 0.440 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 3 | 2022 | 269 | 0.430 |
Why?
|
| Sarcoma, Myeloid | 4 | 2023 | 52 | 0.430 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 982 | 0.420 |
Why?
|
| T-Lymphocytes | 7 | 2018 | 10203 | 0.420 |
Why?
|
| Blast Crisis | 3 | 2024 | 102 | 0.400 |
Why?
|
| Cytogenetic Analysis | 7 | 2022 | 270 | 0.400 |
Why?
|
| Stem Cell Transplantation | 4 | 2018 | 1600 | 0.390 |
Why?
|
| Young Adult | 39 | 2024 | 59199 | 0.390 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2023 | 305 | 0.390 |
Why?
|
| Antigens, CD20 | 3 | 2009 | 199 | 0.390 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 610 | 0.390 |
Why?
|
| Thrombocytopenia | 4 | 2015 | 1182 | 0.390 |
Why?
|
| Genomics | 7 | 2022 | 5828 | 0.390 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2015 | 1640 | 0.380 |
Why?
|
| Erythroid Cells | 3 | 2021 | 237 | 0.380 |
Why?
|
| Cytogenetics | 4 | 2022 | 198 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2024 | 1404 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2018 | 530 | 0.380 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 168 | 0.370 |
Why?
|
|